3236 REFERENCES 1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20. 2. Chaumeil JC. Micronisation: a method of improving the bioavailability of poorlysolubledrugs. Methods Find Exp Clin Pharmacol. 1998;20:211–5. 3. Sheth AR, Bates S, Muller FX, Grant DJW. Polymorphism in piroxicam. Cryst Growth Des. 2004;4:1091–8. 4. Chieng N, Zujovic Z, Bowmaker G, Rades T, Saville D. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1. Int J Pharm. 2006;327:36–44. 5. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solu- bility enhancement in structurally diverse insoluble pharmaceut- icals. Pharm Res. 2010; doi:10.1007/s11095-010-0269-5. 6. Yoshioka M, Hancock BC, Zografi G. Crystallization of indo- methacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83:1700–5. 7. Shamblin SL, Hancock BC, Pikal MJ. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm Res. 2006;23:2254–68. 8. Di L-M, Loeff PI, Bakker H. Atomic disorder in Nb3Sn during heavy mechanical impact. J Less-Common Met. 1991;168:183–93. 9. Desprez S, Decamps M. Transformation of glassy indomethacin induced by ball-milling. J Non-Cryst Solids. 2006;353:4480–5. 10. Willart JF, Caron V, Lefort R, Dandède F, Prèvost D, Decamps M. Athermal character of the solid state amorphization of lactose induced by ball milling. Solid State Commun. 2004;132:693–6. 11. Decamps M, Willart JF, Dudognon E, Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J Pharm Sci. 2007;96:1398–407. 12. Fukuoka E, Markita M, Yamamura S. Some physicochemical properties of glassy indomethacin. Chem Pharm Bull. 1986;34:4314–21. 13. Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci. 2002;91:492– 507. 14. Lam NQ, Okamoto PR, Li M. Disorder-induced amorphization. J Nucl Mat. 1997;251:89–97. 15. Fech HJ. Defect-induced melting and solid-state amorphization. Nature. 1992;356:133–5. 16. Decamps M, Willart JF, Aumelas A. The Glass Transition of Driven Molecular Materials. Complex Systems 5th International Workshop on Complex Systems. 2008;53:61. 17. Shakhtshneider TP, Danède F, Capet F, Willart JF, Decamps M, Myz SA, et al. Grinding of drugs with pharmaceutical excipients at cryogenic temperatures, Part 1. J Therm Anal Calorim. 2007;89:699–707. 18. Sheth AR, Lubach JW, Munson EJ, Muller FX, Grant DJW. Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes. J Am Chem Soc. 2005;127:6641–51. 19. Greaser KA, Strachan CJ, Patterson JE, Gordon KC, Rades T. Physicochemical properties and stability of two differently pre- pared amorphous forms of simvastatin. Cryst Growth Des. 2008;8:128–35. 20. www.drugbank.ca. Adrjanowicz et al. 21. Ogata H, Kawatsu Y, Maruyama Y, Machida K, Haga T. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. Eur J Clin Pharm. 1985;28:53–9. 22. Bundgaard H, Norgaard T, Nielsen NM. Photodegradation and hydrolysis of furosemide and furosemide esters in aqueous solutions. Int J Pharm. 1988;2:217–24. 23. Valladao DMS, De Oliveira LCS, Zuanon Netto J, Ionashiro M. Thermal decomposition of some diuretic agents. J Therm Anal. 1996;46:1291–9. 24. Amin Kreaz RM, Abu-Eida EY, Eros I, Kata M. Freeze-dried complexes of furosemide with β-cyclodextrin dervatives. J Incl Phenom Macrocyclic Chem. 1999;34:39–48. 25. Ghanekar AG, Gupta VG, Gibbs Jr CW. Stability of furosemide in aqueous systems. J Pharm Sci. 1978;67:808–11. 26. Iannuccelli V, Coppi G, Leo E, Fontana F, Bernabei MT. PVP solid dispersion for the controlled pelease of furosemide from a floating multiple-unit system. Drug Dev Ind Pharm. 2000;26:595–603. 27. Shin S-C, Oh I-J, Lee Y-B, Choi H-K, Choi J-S. Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. Int J Pharm. 1998;175:17–24. 28. Villiers MW, Tiedt RL. An analysis of fine grinding and aggregation of poorly soluble drug powders in a vibrating ball mill. Pharmazie. 1996;51:564–7. 29. Kaminski K, Adrjanowicz K, Wojnarowska K, Grzybowska K, Hawelek L, Paluch M, et al. Molecular dynamics of the cryomilled base and hydrochloride Ziprasidones by means of dielectric spectroscopy. J Pharm Sci. 2011; doi:10.1002/jps.22479. 30. Cruz JE, Yakatan GJ. Kinetics and mechanism of hydrolysis of furosemide. Int J Pharm. 1979;2:275–81. 31. Al-Omar IA, Al-Ashban RM, Shah AH. Toxicity studies on 4- chloro-5-sulfamoylanthranilic acid the degradation product of a loop diuretic furosemide. Res J Pharmac. 2009;3:63–77. 32. Moore DE, Sithipitak V. Photolytic degradation of frusemide. J Pharm Pharmacol. 1983;35:489–93. 33. Adrjanowicz K, Grzybowska K, Kaminski K, Hawelek L, Paluch M, Zakowiecki D. Complex studies on physical and chemical stability in liquid and glassy states of Telmisartan (TEL). Solubility advantages given by cryomilled and quenched material. Phil. Mag. in press. 34. Bühler V. Polyvinylpyrrolidone excipients for pharmaceuticals. Berlin: Springer-Verlag; 2005. 35. Doherty C, York P. Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion. J Pharm Sci. 1987;76:731–7. 36. Doherty C, York P. Accelerated stability of an x-ray amorphous furosemide-polyvinylpyrrolidone solid dispersion. Drug Dev Ind Pharm. 1989;15:1969–87. 37. Spamer E, Muller DG, Wessels PL, Venter JP. Characterization of the complexes of furosemide with 2-hydroxypropyl-β-cyclodextrin and sulfobutyl ether-7-β-cyclodextrin. Eur J Pharm Sci. 2002;16:247–53. 38. Beyers H, Malan SF, van der Waat JG, de Villiers MM. Structure-solubility relationship and thermal decomposition of furosemide. Drug Dev Ind Pharm. 2000;36(10):1077–83. 39. McCormick PG, Froes FH. The fundamentals of mechanochemical processing. J Miner Met Mater Soc. 1998;50(11):61–5. 40. Heinickie G. Tribichemistry. Berlin: Akademic-Verlag; 1984. 41. Delogu F, Schiffini L, Cocco G. The invariant laws of the amorphization processes by mechanical alloying. I Experimental findings. Phil Mag A. 2001;81(8):1917–37. 42. Andrade-Gamboa J, Gennari FC, Arneodo Larochette P, Neyertz C, Ahlers M, Pelegrina JL. Stability of Cu-Zn phases under low energy ball milling. Mat Sci Eng A. 2007;447:324–31.